Rachel Lane

H.C. Wainwright & Co. downgraded shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) from Buy to a Neutral rating citing that fundamentals are not holding up. The firm also slashed its target price from $155 to $85 on the stock implying about 5 percent upside potentials from the...